These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 31837960)

  • 21. Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders.
    Dregan A; Chowienczyk P; Molokhia M
    Heart; 2017 Dec; 103(23):1867-1873. PubMed ID: 28601812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiometabolic Disorders in Psoriatic Disease.
    Sobchak C; Eder L
    Curr Rheumatol Rep; 2017 Aug; 19(10):63. PubMed ID: 28844116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriasis and cardiovascular disorders.
    Frieder J; Ryan C
    G Ital Dermatol Venereol; 2016 Dec; 151(6):678-693. PubMed ID: 27627099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.
    Wang J; Wang YM; Ahn HY
    AAPS J; 2014 Sep; 16(5):938-47. PubMed ID: 24993574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein Metabolism and Inflammation in Patients With Psoriasis.
    Armstrong EJ; Krueger JG
    Am J Cardiol; 2016 Aug; 118(4):603-9. PubMed ID: 27392508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammation, atherosclerosis, and psoriasis.
    Siegel D; Devaraj S; Mitra A; Raychaudhuri SP; Raychaudhuri SK; Jialal I
    Clin Rev Allergy Immunol; 2013 Apr; 44(2):194-204. PubMed ID: 22359071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review.
    Mehta H; Narang T; Dogra S; Handa S; Hatwal J; Batta A
    Vasc Health Risk Manag; 2024; 20():215-229. PubMed ID: 38745849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psoriasis and cardiovascular disorders.
    Ryan C; Menter A
    G Ital Dermatol Venereol; 2012 Apr; 147(2):179-87. PubMed ID: 22481581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges.
    Pannu S; Rosmarin D
    Am J Clin Dermatol; 2021 May; 22(3):293-300. PubMed ID: 33586126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiometabolic comorbidities and the approach to patients with psoriasis.
    Gisondi P; Girolomoni G
    Actas Dermosifiliogr; 2009 Dec; 100 Suppl 2():14-21. PubMed ID: 20096157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.
    Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ
    Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting perivascular and epicardial adipose tissue inflammation: therapeutic opportunities for cardiovascular disease.
    Rafeh R; Viveiros A; Oudit GY; El-Yazbi AF
    Clin Sci (Lond); 2020 Apr; 134(7):827-851. PubMed ID: 32271386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis.
    Lima Ede A; Lima MM; Marques CD; Duarte AL; Pita Ida R; Pita MG
    An Bras Dermatol; 2013; 88(6):1029-35. PubMed ID: 24474126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.
    Hu SC; Lan CE
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29065479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammation modulation and cardiovascular disease prevention.
    Awan Z; Genest J
    Eur J Prev Cardiol; 2015 Jun; 22(6):719-33. PubMed ID: 24711609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.
    Wu JJ; Kavanaugh A; Lebwohl MG; Gniadecki R; Merola JF
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):797-806. PubMed ID: 35238067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiovascular risk in systemic inflammatory diseases].
    Marsico F; Parente A; Paolillo S; Casaretti L; Lo Iudice F; Pirozzi E; Conte S; Iardino E; Gambardella F; Della Ratta GL; Cirillo A; Vitagliano A; Filardi PP
    G Ital Cardiol (Rome); 2013; 14(7-8):517-25. PubMed ID: 23877549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha.
    MclInnes IB
    Ernst Schering Res Found Workshop; 2006; (56):29-44. PubMed ID: 16329645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases.
    Manolis AS; Tzioufas AG
    Curr Vasc Pharmacol; 2020; 18(6):533-537. PubMed ID: 32693768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of Visceral Fat and Adipokines with Cardiometabolic Diseases in Psoriasis.
    Goolam Mahyoodeen N; Crowther NJ; Pillay L; Snyman T; Toman M; Daya S; Tikly M
    Acta Derm Venereol; 2019 Dec; 99(13):1218-1223. PubMed ID: 31580467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.